Novo Nordisk https://www.reuters.com/markets/companies/NOVOb.CO” target=”_blank” rel=”noopener”>(NOVOb.CO) said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim …
Read More
About The Author
